Takashi Shigematsu1, Masafumi Fukagawa2, Keitaro Yokoyama3, Takashi Akiba4, Akifumi Fujii5, Motoi Odani6, Tadao Akizawa7. 1. Department of Nephrology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan. taki@wakayama-med.ac.jp. 2. Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan. 3. Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. 4. Sekikawa Hospital, Tokyo, Japan. 5. Clinical Development Planning, Ono Pharmaceutical Co. Ltd, Osaka, Japan. 6. Data Science, Ono Pharmaceutical Co. Ltd, Osaka, Japan. 7. Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Abstract
BACKGROUND: Secondary hyperparathyroidism (SHPT) is a serious major complication in hemodialysis patients with chronic kidney disease. Long-term maintenance of serum phosphate, calcium, and parathyroid hormone (PTH) levels in appropriate ranges in these patients is a major challenge. We investigated the efficacy and safety of long-term treatment with etelcalcetide, a novel intravenous calcimimetic, in Japanese SHPT patients on long-term hemodialysis. METHODS: This study was a multicenter open-label study. A total of 191 hemodialysis patients with serum intact PTH (iPTH) > 240 pg/mL were enrolled. Etelcalcetide was administered thrice weekly for 52 weeks, with an initial dose of 5 mg and flexibility to adjust the dose between 2.5 and 15 mg and to adjust the dosing of concomitant medications for SHPT. The efficacy endpoint was the proportion of patients with serum iPTH decreased to the target range (60-240 pg/mL). RESULTS: Serum iPTH levels decreased immediately after etelcalcetide was started. At the end of the study, 87.5% (95% confidence interval 81.4-92.2; 140/160 patients) of patients achieved target serum iPTH levels, with control of serum calcium and phosphate levels. Adverse events, mostly mild to moderate, were reported by 96.8% of patients and led to study discontinuation in 7.4% of patients. Nausea, vomiting, and symptomatic hypocalcemia were found in 4.7, 9.5, and 1.1%, with 0.5, 1.1, and 1.1% considered treatment-related. CONCLUSIONS: Etelcalcetide effectively maintained serum iPTH, calcium, and phosphate levels in appropriate ranges with concomitant medications for SHPT for 52 weeks in Japanese hemodialysis patients, and was safe and well tolerated. REGISTRATION NUMBER: JapicCTI-142665.
BACKGROUND: Secondary hyperparathyroidism (SHPT) is a serious major complication in hemodialysis patients with chronic kidney disease. Long-term maintenance of serum phosphate, calcium, and parathyroid hormone (PTH) levels in appropriate ranges in these patients is a major challenge. We investigated the efficacy and safety of long-term treatment with etelcalcetide, a novel intravenous calcimimetic, in Japanese SHPT patients on long-term hemodialysis. METHODS: This study was a multicenter open-label study. A total of 191 hemodialysis patients with serum intact PTH (iPTH) > 240 pg/mL were enrolled. Etelcalcetide was administered thrice weekly for 52 weeks, with an initial dose of 5 mg and flexibility to adjust the dose between 2.5 and 15 mg and to adjust the dosing of concomitant medications for SHPT. The efficacy endpoint was the proportion of patients with serum iPTH decreased to the target range (60-240 pg/mL). RESULTS: Serum iPTH levels decreased immediately after etelcalcetide was started. At the end of the study, 87.5% (95% confidence interval 81.4-92.2; 140/160 patients) of patients achieved target serum iPTH levels, with control of serum calcium and phosphate levels. Adverse events, mostly mild to moderate, were reported by 96.8% of patients and led to study discontinuation in 7.4% of patients. Nausea, vomiting, and symptomatic hypocalcemia were found in 4.7, 9.5, and 1.1%, with 0.5, 1.1, and 1.1% considered treatment-related. CONCLUSIONS: Etelcalcetide effectively maintained serum iPTH, calcium, and phosphate levels in appropriate ranges with concomitant medications for SHPT for 52 weeks in Japanese hemodialysis patients, and was safe and well tolerated. REGISTRATION NUMBER: JapicCTI-142665.
Authors: Katrin Uhlig; Jeffrey S Berns; Bryan Kestenbaum; Raj Kumar; Mary B Leonard; Kevin J Martin; Stuart M Sprague; Stanley Goldfarb Journal: Am J Kidney Dis Date: 2010-04-03 Impact factor: 8.860
Authors: Sharon M Moe; John Cunningham; Jürgen Bommer; Stephen Adler; Steven J Rosansky; Pablo Urena-Torres; Moetaz B Albizem; Matthew D Guo; Valter J Zani; William G Goodman; Stuart M Sprague Journal: Nephrol Dial Transplant Date: 2005-07-19 Impact factor: 5.992
Authors: Sarah Walter; Amos Baruch; Jin Dong; James E Tomlinson; Shawn T Alexander; Julie Janes; Tom Hunter; Qun Yin; Derek Maclean; Gregory Bell; Dirk B Mendel; Randolph M Johnson; Felix Karim Journal: J Pharmacol Exp Ther Date: 2013-05-14 Impact factor: 4.030
Authors: Jordi Bover; Pablo Ureña; César Ruiz-García; Iara daSilva; Patricia Lescano; Jacqueline del Carpio; José Ballarín; Mario Cozzolino Journal: Clin J Am Soc Nephrol Date: 2015-07-29 Impact factor: 8.237
Authors: David A Bushinsky; Glenn M Chertow; Sunfa Cheng; Hongjie Deng; Nelson Kopyt; Kevin J Martin; Anjay Rastogi; Pablo Ureña-Torres; Marc Vervloet; Geoffrey A Block Journal: Nephrol Dial Transplant Date: 2020-10-01 Impact factor: 5.992